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\s=b\We examined 99 human immunodeficiency virus (HIV)\p=m-\
negative and 122 HIV-positive intravenous drug users(IVDUs) without acquired immunodeficiency syndrome(AIDS) to determine whether HIV-positive IVDUs had more
neurologic and neuropsychological impairment than their
HIV-negative counterparts. Controlling for age, education,
drug use, history of head injury, and interactions between
head injury and HIV status and drug use, HIV-positive sub-jects had more extrapyramidal signs and frontal release
signs. These findings persisted when asymptomatic HIV-
positive subjects without systemic signs of infection and
HIV-negative subjects were compared. Neurologic findings
were more severe in those with more systemic illness.
Among those reporting a history of head injury with loss of
consciousness, neuropsychological performance was signif-
icantly worse in the HIV-positive subjects, and this in-
creased with severity of illness. This was not true in the
group without head injury, suggesting an interaction be-
tween history of head injury and the seropositive state. No
relationship was noted between head injury and either drug
use or HIV state. Therefore, subtle neurologic and neu-
ropsychological abnormalities may precede clinical evi-
dence of AIDS in IVDUs and may be more evident in those
with head injury.(Arch Neurol. 1992;49:1169-1175)
The association between human immunodeficiency vi¬rus type 1 (HIV-1) and intravenous drug use (IVDTJ)
has been known since 1981.1 Estimates of HIV seropreva-
lence range from 0% to 65% among IVDUs in drug treat¬
ment programs.2 While the rate of HIV seroconversion in
the gay population has stabilized, the rate of seroconver-
sion among IVDUs has continued to increase, up to 14%
annually.2
Little attention has been directed to the neurologic and
neuropsychological consequences of HIV-1 in IVDUs be¬
cause it is difficult to follow them up3"5 and to determine
what neurologic and neuropsychological effects are attrib¬
utable to HIV-1 alone. Drug use may affect performance,
and other factors, such as education, head injury, alcohol




A total of 221 IVDUs (145 men and 76 women) volunteered and
gave informed consent to participate in the study; 168 subjects
were recruited from the Harlem Hospital Infectious Disease
Clinic, New York, NY, and 53 were recruited from the St Luke's/
Roosevelt Methadone Maintenance Clinic, New York, NY.
By definition, all subjects had used intravenous drugs at least
10 times since 1982. The Harlem subjects were not enrolled in a
methadone maintenance program and were also required to have
used intravenous drugs at least once in the year prior to enroll¬
ment. Detailed alcohol and other drug usage history was obtained
for the 6 months and the 24 hours before evaluation.
Subjects who met criteria for acquired immunodeficiency syn¬
drome (AIDS) according to the Centers for Disease Control Na¬
tional Surveillance Criteria (1985)6 on entry were excluded. All
were required to know their HIV status before entry, but
enzyme-linked immunosorbent assay and Western blot analyses
were repeated in all subjects. All subjects were required to speak
English, although it was not necessarily their first language.
Procedure
Overview.—The neurologic examination, performed by a neu¬
rologist, took about 30 minutes. The neuropsychological exami¬
nation was administered by a trained examiner and took about 75
minutes. These two examinations were not always performed on
the same day but were always administered within 1 month. If a
subject was obviously intoxicated or had any alteration in level of
consciousness, he or she was asked to return. This occurred twice
for the neurologic examination and 12 times for the neuropsy¬
chological examination.
Medical Examination.—All subjects underwent a medical ex¬
amination and staging by medical symptoms and signs with use
of a previously described rating scale.7 Subjects were grouped as
follows: (1) HIV negative; (2) HIV positive, completely physically
asymptomatic (these subjects had no physical symptoms or signs
believed to be related to HIV infection that in themselves were
severe enough to warrant clinical attention); (3) HIV positive,
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Table 1.—Description of Neurologie Factors
Factor Name Individual Variables
1 Symptoms Combination of all elicited symp¬
toms: cognitive, motor, and
mood
2 Extrapyramidal Reflects number of extrapyramidal
signs
3 Alternating Reflects number of alternating
movements movement abnormalities
4 Sensory Reflects number of sensory abnor¬
malities
5 Frontal release Reflects number of frontal release
signs
6 Cranial nerve Reflects number of abnormalities
on cranial nerve examination
mildly symptomatic (signs, such as lymphadenopathy, diarrhea
for 2 weeks, or fever for 2 weeks, that would not meet criteria for
stage 3 disease); and (4) HIV positive, symptomatic (significant
medical signs but would not meet criteria for AIDS, eg, oral
thrush, fever or diarrhea for >30 days, or oral hairy leukoplakia).
Neurologic Examination.—Standardized neurologic examina¬
tions were performed before the elicitation of pertinent medical
symptoms and history to be certain that the examiner did not
know the HIV status of the subject. Details of the neurologic ex¬
amination were previously described.8 It included items to rate
extrapyramidal signs from the Unified Parkinson's Disease Rat¬
ing Scale.9 Cognitive function was screened briefly with use of a
19-item mental status test.
Neurologic symptoms were evaluated with a questionnaire
created by Richard Price, MD (unpublished) to assess cognitive
function, motor function, and mood.8 History of seizures, stroke,
multiple sclerosis, psychiatric illness requiring hospitalization,
and head injury with loss of consciousness was elicited.
Analysis of Neurologic Data.—To simplify data analysis, wegrouped individual items into larger categories and used factor
scores derived from factor analysis of signs and symptoms at dif¬
ferent stages of illness.
Individual Signs on Examination—Individual signs were re¬
corded separately, but for purposes of data analysis, some neuro¬
logic signs were grouped as follows: (1) alternating movements, (2)
sensory abnormalities, (3) frontal release signs, (4) cranial nerve
signs, and (5) extrapyramidal signs. The presence of any of the in¬
dividual signs rendered the whole category positive, while the ab¬
sence of all the signs in a category rendered the category negative.
Factor Creation.—We used neurologic data for the entire
cohort of HIV-positive and HIV-negative subjects for a factor
analysis. A total of 77 individual variables were reduced to eight
summary variables. These eight summary variables were in¬
cluded in a principal components factor analysis with subsequent
VARIMAX rotation. Six factors were produced (Table 1). Factor
analysis provided a description of severity of illness because the
number of abnormalities, rather than just presence or absence,
was reflected in each factor.
Neuropsychological Examination.—The neuropsychological
examination, performed by an investigator "blinded" to HIV sta¬
tus, assessed a range of cognitive functions (Table 2). The battery
was a truncated version of one described elsewhere.8
Analysis of Neuropsychology Data.—Neuropsychological
test performance was evaluated in two ways, as described below.
Comparisons With Normal Data.—One set of summary mea¬
sures was based on the number of SDs from the group mean per¬
formance for each subject for each test expressed in terms of  
scores. Tests were subdivided into cognitive functions: general
intelligence, memory, language, executive, visuospatial, atten¬
tion, and motor speed. Performance in each area was considered
defective if one test score was 2 or more SDs or greater below the
Table 2.—Individual Neuropsychological Tests and theCognitive Areas They Represent
General intelligence




Visual Reproduction subtest of Wechsler Memory Scale14
Language
Boston Naming Test15
Controlled Oral Word Association Test16
Animal Naming17
Executive
Odd Man Out Test18








Trail Making Test Part A19
*WAIS-R indicates Wechsler Adult Intelligence Scale-Revised.
mean. Overall performance was considered defective if two or
more areas were impaired. The mean of  scores for all tests in
each area was calculated as a summary score.
Clinical Impression.—Neuropsychological performance graded
normal, borderline, or abnormal was assessed by two experienced
neuropsychologists (Y.S. and M.S.) who were blinded to HIV status.
Risk Behavior Assessment.—All subjects were systematically
questioned about alcohol and other drug use. A variable was cre¬
ated to represent any drug use in the 6 months preceding the ini¬
tial evaluation. Any use of cocaine, heroin, benzodiazepines, hal¬
lucinogens, or phencyclidine was considered a positive history.
For a subset of subjects (n=146), information on frequency of drug
use was available. Drug use of less than two to six times per week
was considered low-frequency use, and any amount greater than
this was considered high-frequency drug use. Alcohol use was
considered separately. Alcohol and other drug use for the 24
hours before evaluation was rated as yes or no. All the same drugs
were included, with the addition of marijuana.
Statistical Analysis
Age, education, and CD4 cell counts were contrasted in HIV-
positive and HIV-negative subjects with independent sample t
tests. Individual neuropsychological test scores in subjects with
and without head injury within HIV-positive and HIV-negative
groups were compared with the use of independent sample t
tests. Categories describing the presence or absence of individual
signs were examined with the use of Pearson's  2 tests.
Neurologic and neuropsychological indexes were contrasted in
HIV-positive and HIV-negative subjects with the use of multi¬
variate analysis of variance (MANOVA). Individual main effects
and interactions were included in each model based on prelim¬
inary analysis of their significance. The MANOVA for the neuro¬
logic indexes (the six factors listed in Table 1) included the
following main effects: serostatus, history of head injury with loss
of consciousness, current IVDU, and head injury X IVDU and
head injury X serostatus interactions. Age and educational level
were covariates. In the neuropsychological model, the following
main effects were examined: serostatus, sex, first language, and
history of head injury with loss of consciousness. A serostatus X
head injury interaction was also included in the model, but a head
injury X IVDU interaction was not, based on preliminary obser-
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"Values in parentheses are SDs. HIV indicates human immunodefi¬
ciency virus.
+P<.01.
vations of no relationship between these variables. Years of edu¬
cation and age were included as covariates.
For the neurologic and neuropsychological models, after con¬
trasting seropositive and seronegative patients, two additional
approaches were taken to grouping subjects. In the first approach,
HIV-positive subjects were subdivided into two stages—
asymptomatic plus mildly symptomatic and symptomatic but not
having AIDS. Analyses of variance (ANOVAs) and Bartholom¬
ew's test for nonlinearity22 were performed on neurologic factor
scores and on individual neuropsychological test scores in the
HIV-positive and HIV-negative groups to determine between-
group differences and whether there was a linear relationship
between stage of illness and test scores. In the second approach,
a direct contrast was made between HIV-positive and HIV-
negative asymptomatic subjects.
For a subset of 146 subjects in whom frequency of drug use was
available, two-way ANOVA was performed with HIV status and
high- and low-frequency drug use as main effects.
RESULTS
Demographics
A total of 145 men and 76 women underwent neurologic
and neuropsychological examinations. The cohort com¬
prised 122 HIV-positive subjects (83 men and 39 women)
and 99 HIV-negative subjects (62 men and 37 women). Of
the HIV-positive subjects, 33 (27%) (24 men and nine
women) were completely physically asymptomatic; 28(23%) (22 men and six women) had mild medical signs,
such as lymphadenopathy, and 61 (50%) (37 men and 24
women) had medical signs of HIV infection but did not
meet criteria for AIDS.
The HIV-positive and HIV-negative subjects were com-
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*Values in parentheses are SDs. HIV indicates human immunodefi¬
ciency virus.
parable in age, gender, education, ethnic group, primary
language, and handedness. There was no significant dif¬
ference in medical history of seizures or cerebrovascular
accidents reported by HIV-positive and HIV-negative
subjects. Head injury with loss of consciousness was no
different for HIV-positive and HIV-negative subjects. The
mean CD4 cell count for HIV-negative subjects was
1.07X10YL compared with 0.42X109/L for HIV-positive
subjects (Table 3).
When HIV-positive and HIV-negative subjects were
separated into those with and without head injury, no sig¬
nificant differences were seen in any of the demographic
variables (Table 4).
Relationship of Drug Use to HIV
Infection and Head Injury
Frequency of drug use was examined in relation to HIV
status and head injury. When drug use was categorized as
high or low frequency, a relationship between high-
frequency drug use in the 6 months before evaluation and
HIV-positive state was seen ( 2 [1 df], 3.81; P<.05). To fur¬
ther examine the relationship between frequency of drug
use and HIV status, subjects were categorized as high- or
low-frequency users according to stage of infection. The
percentage of high-frequency drug users was as follows:
HIV negative, 75%; asymptomatic, 95%; mildly symptom¬
atic, 65%; and moderately symptomatic but not AIDS, 87%.
Although HIV-positive subjects used drugs more fre¬
quently than did HIV-negative subjects, no relationship
between frequency of drug use and stage of infection was
seen.
No relationship between history of head injury and
high- or low-frequency drug use was seen in the entire co-
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Table 5.—Mean Scores for Each of Six Neurologic






























*HIV indicates human immunodeficiency virus; ANOVAs, analyses of
variance. Values are mean scores. Values in parentheses are the num¬
ber of subjects demonstrating each factor on examination.
tMild medical signs, eg, lymphadenopathy.
^Combination of elicited symptoms (cognitive, motor, and mood).§P<.01.
hört or when HIV-positive and HIV-negative subjects were
considered separately.
Neurologic Signs
No differences were seen in the percentages of HIV-
positive and HIV-negative subjects who had any impair¬
ment in cranial nerves, fine alternating movements, or
sensory perception. Significantly more HIV-positive than
HIV-negative subjects had extrapyramidal signs (P<.02)
and frontal release signs (P<.002).
Rigidity was the only extrapyramidal sign present more
often in the HIV-positive subjects (7.4%) than in the HIV-
negative subjects (0%). Tremor, bradykinesia, postural in¬
stability, or hypomimia occurred rarely but at similar fre¬
quencies in HIV-positive and HIV-negative subjects.
Neurologic Symptoms
Frequency of impaired concentration, memory, or word-
finding difficulty did not differ in HIV-positive and HIV-
negative subjects, and no differences were seen in the re¬
ported frequency of motor dysfunctions, such as impaired
dexterity or gait or reported disorders of mood (depres¬
sion, apathy, or emotional lability).
Neurologic Factors
Mean scores for each of the six factors in HIV-negative
patients and two stages of HIV-positive patients—
asymptomatic or mildly symptomatic and HIV-positive
symptomatic but not AIDS—were contrasted with the use
of one-way ANOVAs (Table 5). Between-group differences
were seen only for the extrapyramidal factor and the fron¬
tal factor. These two factor scores showed a linear increase
with stage of illness, suggesting that subjects with more
systemic illness also had more extrapyramidal and frontal
release signs.
The six neurologic factors were included in a MANOVA,
with the main effects of serostatus (HIV positive vs HIV
negative), current IVDU (present or absent), head injury(present or absent), a serostatus X IVDU interaction, and
a serostatus X head injury interaction, covaried by age and
education. The overall MANOVA was significant(P<.001), as were serostatus (Hotelling  2=. , P<.002),
Table 6.—Number of Cognitive Areas With a Test




s-2 HIV Negative HIV Positive
*HIV indicates human immunodeficiency virus. Values in parenthe¬
ses are percent of total.
head injury with loss of consciousness (Hotelling T2=.08,
P<.02), and IVDU (Hotelling T*=.14, P<.001) main effects.
In follow-up univariate F tests, a significant serostatus
effect was seen for extrapyramidal signs (F=7.3, P<.008),
sensory abnormalities (F=6.9, P<.009), and frontal release
signs (F=6.7, P<.01). When all other main effects and co¬
variates were controlled, HIV-positive subjects had signif¬
icantly more extrapyramidal signs, frontal release signs,
and sensory signs.
In a second MANOVA, stage of illness was substituted
for serostatus as follows: (1) HIV negative; (2) HIV positive,
asymptomatic; (3) HIV-positive, mildly symptomatic; and(4) HIV positive, moderately symptomatic. The MANOVA
remained highly signficant (P<.001). Stage of illness (Ho¬
telling T=.2\, P<.003), head injury (Hotelling TV08,
P<.02), and IVDU (Hotelling T2-10, P<.006) main effects
were all significant.
In follow-up univariate F tests, a significant stage-of-
illness main effect was seen for symptoms (F=4.2, P<.007),
extrapyramidal signs (F=4.2, P<.007), and frontal release
signs (F=2.7, P<.04). Therefore, with all other main effects
and covariates controlled, subjects with the most systemic
illness also had the highest frequencies of neurologic signs
and symptoms.
A third MANOVA contrasted HIV-negative and HIV-
positive asymptomatic patients. The MANOVA was sig¬
nificant (P<.05), and the HIV negative/HIV positive con¬
trast was the only significant main effect (Hotelling T2=.\3,
P<.03).
In follow-up univariate F tests, a significant serostatus
effect was seen for extrapyramidal (F=5.4, P<.02), sensory(F=4.2, P<.04), and frontal release (F=4.8, P<.03) signs, in¬
dicating that even when the comparison was limited to as¬
ymptomatic HIV-positive subjects and HIV-negative sub¬jects, significant increases in neurologic signs were seen.
Neuropsychological Summary Scores
No difference was seen between HIV-positive and HIV-
negative subjects in the distribution of ratings of overall
performance by the neuropsychologist's impression or in
the frequency of defective summary scores (Table 6).
We calculated a set of omnibus MANOVAs. The overall
MANOVA was significant (P<.001). Neither the overall
serostatus (HIV positive vs HIV negative) or serostatus X
head injury interaction effect reached significance. How
ever, in follow-up univariate F tests, a significant serosta¬
tus X head injury main effect was seen for tests of mem-
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Table 7.—A Comparison of Human Immunodeficiency Virus (HIV)-Negative and HIV-Positive Subjects With andWithout a History of Head Injury*
No Head Injury Head Injury
HIV Negative
I
HIV Positive HIV Negative
I
HIV Positive
Modified Mini-Mental State examination 50.0(4.5) 50.2(4.3) 50.4(3.4) 47.7(5.6)+
Selective Reminding Test
Total recall 50.4(10.5) 51.7(8.1) 50.4(9.7) 46.8(11.9)
Long-term retrieval 42.2(15.4) 44.2(12.3) 42.1(12.7) 35.7(14.1)+
Long-term storage 45.3(14.9) 47.3(12.5) 45.4(13.0) 38.7(14.5)+
Consistent long-term retrieval 34.5(17.5) 36.2(14.1) 34.6(13.7) 27.7(13.9)+
Delayed recall 7.7(3.1) 8.4(2.6) 7.7(2.8) 7.0(2.9)
Boston Naming Test 23.3(4.7) 23.9(4.0) 24.5(4.0) 21.8(5.3)+
WAIS-R Block Design 18.7(8.4) 22.1(9.5) 22.7(8.9) 18.1(7.9)+
Wechsler Memory Scale
Visual reproduction subtest 29.1(7.4) 30.2(5.6) 29.4(7.4) 26.6(14.1)
Delayed visual reproduction subtest 22.4(9.3) 23.6(9.1) 23.8(9.2) 18.1(9.2)+
Cancellations (omissions) 0.5(0.96) 1.9(11.2) 0.7(1.3) 1.3(1.4)
Grooved pegboard, nondominant 88.6(24.3) 89.9(20.2) 82.5(25) 100.3(29.4)+
Digit Symbol (raw score) 43.4(13.0) 45.7(12.4) 43.4(11.4) 39.4(12.0)
Trail Making Test Part  (sec) 111.6 (60.9) 106.9 (52) 115.3 (75) 130.2 (59.7)
Neuropsychologist's clinical impression 1.1(0.89) 1.0(0.88) 1.0(0.92) 1.4(0.79)+
*Two-way analysis of variance was performed. WAIS-R, indicates Wechsler Adult Intelligence Scale-Revised. Values are mean (SD) scores.
+P<.05 significant HIV status X head injury interactions.
ory (F=5.5, P<.02), language (F=3.7, P<.05), and visuo¬
spatial ability (F=5.3, P<.02).
In a second MANOVA, when serostatus was replaced in
the MANOVA by stage-of-illness (HIV negative vs three
stages of HIV positive), stage-of-illness and serostatus X
head injury main effects were not significant, nor were any
of the univariate F tests.
Finally, in a third MANOVA, HIV-positive and HIV-
negative asymptomatic subjects were contrasted. The
overall MANOVA was significant (P<.004), but the HIV
negative/HIV positive contrast and the serostatus X head
injury interaction were not. In the follow-up univariate F
test, a significant serostatus effect was seen for executive
function (F=5.3, P<.02).
Individual Neuropsychology Test Scores
Mean individual test scores were calculated for subjects
with or without head injury within HIV-positive and
HIV-negative groups (Table 7). With the use of two-way
ANOVAs with HIV status and history of head injury as
main effects, significant differences were present in the
subjects with head injury on a number of individual tests.
No differences were seen between HIV-positive and HIV-
negative subjects within the subject group without head
injury. There was an interaction between HIV status and
history of head injury for most variables (Figure).
Subjects with and without head injury were then di¬
vided by stage of illness: (1) HIV negative; (2) HIV,
asymptomatic and mildly symptomatic; and (3) HIV pos¬
itive, symptomatic but not AIDS. No between-group dif¬
ferences were seen in subjects without head injury. In con¬
trast, in the subjects with head injury, there was a linear
relationship between stage of illness and neuropsycholog¬
ical test performance on the Mini-Mental State examina¬
tion, Selective Reminding Test, Delayed Visual Reproduc¬
tion subtest of the Wechsler Memory Scale, and the
grooved pegboard. More severe stage of illness was asso¬
ciated with worse neuropsychological test performance in
%3
HIV Negative HIV Positive
HIV Status
Performance on the Selective Reminding Test (long-term retrieval) in
subjects with (circle) and without (square) head injury. An interaction
between head injury and human immunodeficiency virus-positive (HIV)
state is seen.
the subjects with head injury only, again suggesting an in¬
teraction between HIV status and head injury (Table 8).
Individual neuropsychological tests were included in a
MANOVA with serostatus, head injury, first language, sex,
and a serostatus X head injury interaction main effects,
covaried by age and education. Neither serostatus nor the
serostatus  head injury interaction was a significant main
effect. When univariate F tests were inspected, there were
significant serostatus X head injury interactions for the
Mini-Mental State examination (F=4.5, P<.04), the Boston
Naming Test (F=5.5, P<.02), the Wechsler Adult Intelli¬
gence Scale-Revised (WAIS-R) Block Design (F=5.9,
P<.02), WAIS-R Similarities (F=4.1, P<.05), Wechsler
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Table 8.—Relationship Between Stage of Illness and
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Mini-Mental State












Reproduction 23.8(9.2) 20.3(10.6) 15.8(6.2)+
Grooved pegboard,
nondominant 82.5(25.6) 92.7(26.3) 107.8(30.8)+
*HIV indicates human immunodeficiency virus. Values are mean (SD)
scores on neuropsychological tests compared by analyses of variance.
+P<.05.
Memory Scale Visual Reproduction subtest (F=4.7, P<.03),
and Delayed Visual Reproduction (F=4.6, P<.03). The in¬
teractions suggested that the performance was more im¬
paired in HIV-positive patients who sustained head injury.
When the serostatus was replaced with HIV stage in the
MANOVA model (HIV negative and three medical stages of
HIV positive), the stage-of-illness main effect was not signif¬
icant. In the univariate F tests, there was a significant HIV
stage effect for the modified Mini-Mental State examination(F=2.9, P<.04) and the Boston Naming Test (F=3.7, P<.01).
No significant stage  head injury interaction was seen.
When HIV-positive and HIV-negative asymptomatic
subjects were contrasted, a significant HIV positive/HIV
negative main effect was seen (Hotelling T2=A3, P<.02),but the serostatus X head injury interaction was not
significant. Univariate F tests did not reveal an HIV status
or an interaction effect for any individual tests.
COMMENT
The influence of HIV on neurologic and neuropsycho¬
logical function is difficult to determine in IVDUs for many
reasons. First, the group is demographically diverse and
includes men and women with a wide range of cultural
and educational backgrounds. Second, many subjects have
complex medical histories that include head trauma with
loss of consciousness. Third, long-term drug use may af¬
fect neuropsychological test performance or the presence
of neurologic signs. Also, acute intoxication (alcohol or
other drugs) can affect performance. We therefore took a
conservative approach to these preliminary analyses, con¬
trolling statistically for these possible effects. In addition,
we used omnibus MANOVAs to adjust for multiple com¬
parisons. Nevertheless, two major findings emerged from
this cross-sectional approach.
First, the only neurologic findings that differed between
the HIV-positive and the HIV-negative subjects were the
presence of extrapyramidal signs, most notably rigidity,
and frontal release signs. These increased in linear fashion
with stage of illness, appearing most prominent in those
with the most systemic illness. When current IVDU, head
injury, age, and education were included in an omnibus
MANOVA, these findings persisted and were present even
when totally asymptomatic HIV-positive subjects were
contrasted with HIV-negative subjects.
Second, there was no difference in the frequency of de¬
fective neuropsychological scores between HIV-positive
and HIV-negative subjects. Examination of neuropsycho¬
logical summary scores included within a MANOVA
revealed no significant serostatus main effects but did re¬
veal a number of univariate head injury X HIV status in¬
teractions. When individual neuropsychological tests were
included in a MANOVA, again no significant main effects
were seen, although many univariate head injury X HIV
status interactions were noted. A total of 157 cases were
included in this analysis. Because the MANOVAs were
suggestive of specific relationships and were limited by
smaller sample size, a simpler analysis, a two-way
ANOVA with status and head injury main effects, was
utilized, including all 221 subjects. A head injury X
serostatus interaction was evident on numerous tests.
Many of these tests showed a worsening with stage of in¬
fection within the group with head injury only. The signif¬
icant interaction between serostatus and head injury sug¬
gests that the effect of HIV on performance may be additive
if there has been a brain injury.
We found that the moderately symptomatic subjects
who did not meet criteria for AIDS had more extrapyra¬
midal signs and frontal release signs. This finding is con¬
sistent with the idea that neurologic signs and symptoms
increase with systemic disease and decline with immune
function.23 Early motor symptoms of HIV-1-associated
cognitive impairment include gait impairment, leg weak¬
ness, and tremor.24 In patients with HIV-1-associated de¬
mentia complex, neurologic findings include frontal re¬
lease signs, slowed rapid alternating movements, gait
impairment, hyperreflexia, hypertonia, and peripheral
neuropathy.25. Our finding of extrapyramidal signs and
frontal release signs even in those without systemic illness
compared with HIV-negative subjects may reflect early
subcortical hypermetabolism, which has been described in
the early stages of HIV dementia with the use of positron
emission tomography.26
Whether specific behavior patterns predispose to ner¬
vous system dysfunction, including exposure to HIV
infection and head trauma, deserves further exploration.
No attempt was made at the time of the initial assessment
to determine duration of unconsciousness, age at the time
of head injury, or number of head injuries. We have
included a more detailed head injury questionnaire in
subsequent evaluations, including age at time of head in¬jury, number of incidents, duration of loss of conscious¬
ness, and need for hospitalization. Magnetic resonance
imaging evaluations in 115 of the IVDUs at subsequent
evaluations will also provide further documentation of the
degree of brain injury.
Few studies have documented neurologic impairment in
IVDUs. In a retrospective study of HIV infection conducted
before the advent of HIV antibody testing, 64% of subjects
were IVDUs and 23% had abnormal neurologic signs.3
In another survey of asymptomatic HIV-positive and
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HIV-negative IVDUs, neurologie abnormalities were
equally prevalent: 81 % of the seropositive group and 76%
of the seronegative group.5-27 In a subsequent study of this
cohort of 109 HIV-positive, predominantly mildly symp¬
tomatic and 51 HIV-negative subjects, Royal et al28 found
neurologic signs with similar frequency in seropositive
and seronegative groups. Neuropsychological perfor¬
mance was similar in HIV-positive and HIV-negative
groups, except for the Digit Span tests. When these tests
were examined with an ANOVA, only education was sig¬
nificantly associated with the outcome. Royal et al did not
report an interaction effect between serostatus and head
injury with loss of consciousness, although head injury
was common: HIV positive, 18%; HIV negative, 35%. The
higher frequency of head injury and alcohol use in the se¬
ronegative subjects may have made any differences asso¬
ciated with serostatus more difficult to detect.
In a prospective survey at Harlem Hospital Center, New
York, NY, of 190 inpatients with AIDS or AIDS-related
complex, 80% were IVDUs and 91 % had neurologic symp¬
toms or signs, the most common of which was altered
mental status, followed by focal cerebral signs.4
No difference was noted between IVDUs and non-
IVDUs in the prevalence of neurologic findings, nor was
there a difference in neurologic findings between pa¬
tients with AIDS and lymphadenopathy/AIDS-related
complex. Clearly, the heightened awareness of the neu¬
rologic complications of HIV-1 infection, a detailed neu¬
rologic examintion, and detection of seropositivity in a
high-risk patient population accounted for the higher
frequency in the prospective study.
Neuropsychological impairment was found by McKeg-
ney et al29 in finger tapping, Digit Span (forward), and
WAIS-R Similarities measures when 83 HIV-positive
IVDUs were compared with 137 HIV-negative IVDUs.
Follow-up examinations of 91 patients 7 months after thebaseline visit showed similar findings without deteriora¬
tion of function.
In contrast, in Edinburgh, no significant differences were
noted in cognitive function between the HIV-positive and
HIV-negative IVDUs. The authors of the Edinburgh study
concluded that AIDS dementia is a late complication of
HIV infection and that intellectual impairment is more
likely due to drug use.30
Our data indicate that IVDUs who do not have AIDS
show similar but less severe neurologic and neuropsycho¬
logical impairment than those seen in patients with AIDS.
These signs are more apparent in those with more ad¬
vanced disease. Neuropsychological impairment was
present only among HIV-positive subjects with a history of
head injury and loss of consciousness. When HIV-positive
subjects were compared with HIV-negative subjects in the
population without head injury, no differences were seen,
suggesting an interaction between head injury and HIV
status. Further attention must be given to head injury as a
contributor to neuropsychological impairment in HIV-
infected individuals.
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